Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2001 1
2004 1
2005 1
2007 1
2009 2
2010 2
2013 1
2014 1
2016 1
2017 2
2018 1
2021 1
2022 2
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

15 results

Results by year

Filters applied: . Clear all
Page 1
Preclinical evaluation of FAP-2286 for fibroblast activation protein targeted radionuclide imaging and therapy.
Zboralski D, Hoehne A, Bredenbeck A, Schumann A, Nguyen M, Schneider E, Ungewiss J, Paschke M, Haase C, von Hacht JL, Kwan T, Lin KK, Lenore J, Harding TC, Xiao J, Simmons AD, Mohan AM, Beindorff N, Reineke U, Smerling C, Osterkamp F. Zboralski D, et al. Among authors: osterkamp f. Eur J Nucl Med Mol Imaging. 2022 Sep;49(11):3651-3667. doi: 10.1007/s00259-022-05842-5. Epub 2022 May 24. Eur J Nucl Med Mol Imaging. 2022. PMID: 35608703 Free PMC article.
Feasibility, Biodistribution, and Preliminary Dosimetry in Peptide-Targeted Radionuclide Therapy of Diverse Adenocarcinomas Using 177Lu-FAP-2286: First-in-Humans Results.
Baum RP, Schuchardt C, Singh A, Chantadisai M, Robiller FC, Zhang J, Mueller D, Eismant A, Almaguel F, Zboralski D, Osterkamp F, Hoehne A, Reineke U, Smerling C, Kulkarni HR. Baum RP, et al. Among authors: osterkamp f. J Nucl Med. 2022 Mar;63(3):415-423. doi: 10.2967/jnumed.120.259192. Epub 2021 Jun 24. J Nucl Med. 2022. PMID: 34168013 Free PMC article.
Fibroblast activation protein targeted radiotherapy induces an immunogenic tumor microenvironment and enhances the efficacy of PD-1 immune checkpoint inhibition.
Zboralski D, Osterkamp F, Christensen E, Bredenbeck A, Schumann A, Hoehne A, Schneider E, Paschke M, Ungewiss J, Haase C, Robillard L, Simmons AD, Harding TC, Nguyen M. Zboralski D, et al. Among authors: osterkamp f. Eur J Nucl Med Mol Imaging. 2023 Jul;50(9):2621-2635. doi: 10.1007/s00259-023-06211-6. Epub 2023 Apr 22. Eur J Nucl Med Mol Imaging. 2023. PMID: 37086273 Free PMC article.
SAR of N-phenyl piperidine based oral integrin alpha5beta1 antagonists.
Zischinsky G, Osterkamp F, Vossmeyer D, Zahn G, Scharn D, Zwintscher A, Stragies R. Zischinsky G, et al. Among authors: osterkamp f. Bioorg Med Chem Lett. 2010 Jan 1;20(1):65-8. doi: 10.1016/j.bmcl.2009.11.030. Epub 2009 Nov 14. Bioorg Med Chem Lett. 2010. PMID: 19959360
Discovery of orally available integrin alpha5beta1 antagonists.
Zischinsky G, Osterkamp F, Vossmeyer D, Zahn G, Scharn D, Zwintscher A, Stragies R. Zischinsky G, et al. Among authors: osterkamp f. Bioorg Med Chem Lett. 2010 Jan 1;20(1):380-2. doi: 10.1016/j.bmcl.2009.10.073. Epub 2009 Oct 28. Bioorg Med Chem Lett. 2010. PMID: 19910191
15 results